Publications by authors named "A Molinos-Quintana"
Successful allogeneic CD34 hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Bone Marrow Transplant
November 2024
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Front Immunol
February 2024
[This corrects the article DOI: 10.3389/fimmu.2023.
View Article and Find Full Text PDFImpact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Front Immunol
February 2024
Article Synopsis
- Loss of B-cell aplasia (BCA) is linked to the effectiveness of CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia, with most relapses occurring in the first months post-infusion, particularly in patients with high tumor burden (HTB).
- A study of 73 patients showed that those with HTB had significantly lower event-free survival (EFS) rates (19.3%) compared to those with low tumor burden (LTB) (67.2%), and relapses were more likely to be CD19-negative in the HTB group.
- The findings suggest that BCA loss is associated with a higher risk of CD19-positive relapses and that patients with HTB might benefit from additional
Article Synopsis
- Children with a type of cancer called acute lymphoblastic leukaemia (ALL) usually have good chances of survival, but some of them might get sick again (called relapse).
- Researchers are using a special method called topological data analysis (TDA) to look at patient data and predict who is more likely to relapse, especially those who were thought to be low risk.
- They suggest three ways to analyze data to help doctors understand the risks better, using things like visual checks or advanced math and machine learning with certain important markers (CD10, CD20, CD38, and CD45).
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.
Front Immunol
May 2023
Purpose: CAR-T cell therapy has proven to be a disruptive treatment in the hematology field, however, less than 50% of patients maintain long-term response and early predictors of outcome are still inconsistently defined. Here, we aimed to optimize the detection of CD19 CAR-T cells in blood and to identify phenotypic features as early biomarkers associated with toxicity and outcomes.
Experimental Design: In this study, monitoring by flow cytometry and digital PCR (dPCR), and immunophenotypic characterization of circulating CAR-T cells from 48 patients treated with Tisa-cel or Axi-cel was performed.